Consensus AbbVie Inc. Xetra

Stocks

4AB

US00287Y1091

Pharmaceuticals

Market Closed - Xetra 11:35:40 2026-09-30 EDT			5-day change	1st Jan Change
232.50 ^EUR	+0.09%		-0.13%	+18.26%

09-30	AbbVie Presents Detailed Phase 1 Data For ABBV-295, A Long-Acting Amylin Analog, Demonstrating Favorable Tolerability And Pharmacokinetic Profile At EASD 2026	CI
09-30	AbbVie unveils promising results for its obesity drug candidate

442a49.JZLrwRvdc9VeN3lLP4kkuoTlyILS9yhVTeWCjOrUi_s.YsG8iWOXHq1tZzN7dvFw2MG8_PbrgRoEP431-IGXwMJ92NuNYZEVtwpFOA~5905cba639d792512f7300b7b1b56420

Analysts' recommendations: AbbVie Inc.

09-29	AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says	MT
09-29	BofA Securities Adjusts AbbVie Price Target to $289 From $282, Maintains Buy Rating	MT
09-24	Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says	MT
09-10	HSBC Adjusts Price Target on AbbVie to $315 From $300, Keeps Buy Rating	MT
09-08	BofA Securities Adjusts Price Target on AbbVie to $282 From $276	MT
08-20	Piper Sandler Adjusts Price Target on AbbVie to $303 From $298, Maintains Overweight Rating	MT
08-17	Wells Fargo Adjusts Price Target on AbbVie to $300 From $295, Keeps Overweight Rating	MT
08-13	Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300	MT
08-11	BNP Paribas Adjusts Price Target on AbbVie to $247 From $218, Maintains Neutral Rating	MT
08-05	Argus Lifts AbbVie Price Target to $270 From $250	MT
08-05	Leerink Partners Adjusts Price Target on AbbVie to $279 From $245	MT
08-04	Guggenheim Adjusts Price Target on AbbVie to $288 From $261, Maintains Buy Rating	MT
08-04	Rothschild & Co Redburn Adjusts Price Target on AbbVie to $285 From $284, Maintains Buy Rating	MT
08-03	AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says	MT
08-03	Oppenheimer Adjusts AbbVie Price Target to $258 From $244, Maintains Neutral Rating	MT
08-03	Canaccord Genuity Adjusts AbbVie Price Target to $290 From $282, Maintains Buy Rating	MT
07-31	JPMorgan Adjusts Price Target on AbbVie to $285 From $280	MT
07-28	Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating	MT
07-22	Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating	MT
07-15	Citigroup Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating	MT
07-13	BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating	MT
07-13	UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating	MT
07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
07-10	BofA Securities Adjusts AbbVie Price Target to $276 From $234	MT
07-10	AbbVie's Q2 Results Expected to be Inline With Expectations, RBC Says	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+12.17%
	JOHNSON & JOHNSON					+4.37%
	ABBVIE INC.					+5.91%
	MERCK & CO., INC.					+4.29%
	ROCHE HOLDING AG					+7.46%
	NOVARTIS AG					+5.11%
	ASTRAZENECA PLC					+28.35%
	AMGEN INC.					-7.72%
	GILEAD SCIENCES, INC.					+4.87%
	Average					+7.20%
	Weighted average by Cap.					+7.93%